Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022033
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Announcement on the non-public offering of shares that there is no financial assistance or compensation provided directly or through stakeholders to investors participating in the subscription
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) on 2022
On March 4, 2022, the fourth interim meeting of the Fifth Board of directors was held, which was deliberated and passed
After passing the proposal related to the non-public offering of shares, we hereby promise that the company does not provide financial assistance or compensation to investors participating in the subscription directly or through stakeholders, as follows:
The company does not make a commitment to the minimum guarantee income or disguised minimum guarantee income to the investors participating in the subscription, and does not provide financial assistance or compensation to the investors participating in the subscription directly or through stakeholders.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 6, 2022
